'If we don't have consent, we need to have beneficence': Requiring beneficence in nonconsensual neurocorrection.

beneficence consent criminal rehabilitation neurocorrectives neurolaw protections against abuse

Journal

Bioethics
ISSN: 1467-8519
Titre abrégé: Bioethics
Pays: England
ID NLM: 8704792

Informations de publication

Date de publication:
09 2022
Historique:
revised: 05 02 2022
received: 08 09 2021
accepted: 08 04 2022
pubmed: 20 5 2022
medline: 23 8 2022
entrez: 19 5 2022
Statut: ppublish

Résumé

Neurointerventions-interventions that cause direct physical, chemical or biological effects on the brain-are sometimes administered to criminal offenders for the purpose of reducing their recidivism risk and promoting their rehabilitation more generally. Ethical debate on this practice (henceforth called 'neurocorrection') has focused on the issue of consent, with some authors defending a consent requirement in neurocorrection and others rejecting this. In this paper, I align with the view that consent might not always be necessary for permissible neurocorrective use, but introduce a qualification I argue ought to inform our ethical and legal analysis of neurocorrection if we are to administer neurocorrectives nonconsensually. I maintain our use of nonconsensual neurocorrection should be constrained by a beneficence requirement-that it should be limited to neurocorrectives that can be expected to benefit those required to undergo them; and my argument is that a beneficence requirement is necessary in order to safeguard against offender abuse. I highlight how we afford a heightened protective role to beneficence in other instances of biomedical intervention where consent is absent or in doubt; and I argue a beneficence requirement is also necessary in the correctional context because alternative candidate protections would provide insufficiently strong safeguards on their own. I then consider whether requiring beneficence in nonconsensual neurocorrection would (a) be incompatible with penal theory, (b) be objectionably paternalistic, or (c) foreclose many fruitful avenues of crime control. I argue in each case that it would not.

Identifiants

pubmed: 35586936
doi: 10.1111/bioe.13043
pmc: PMC9544543
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

774-782

Subventions

Organisme : Wellcome Trust
ID : 217709/Z/19/Z
Pays : United Kingdom

Informations de copyright

© 2022 The Authors. Bioethics published by John Wiley & Sons Ltd.

Références

Bioethics. 2022 Sep;36(7):774-782
pubmed: 35586936

Auteurs

Emma Dore-Horgan (E)

Uehiro Centre for Practical Ethics, University of Oxford, Oxford, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH